Glioblastoma, the most aggressive and least treatable form of malignant glioma, is the most common human brain tumor. Although many regions of allelic loss occur in glioblastomas, relatively few tumor suppressor genes have been found mutated at such loci. To address the possibility that epigenetic alterations are an alternative means of glioblastoma gene inactivation, we coupled pharmacological manipulation of methylation with gene profiling to identify potential methylation-regulated, tumor-related genes. Duplicates of three short-term cultured glioblastomas were exposed to 5 lM 5-aza-dC for 96 h followed by cRNA hybridization to an oligonucleotide microarray (Affymetrix U133A). We based candidate gene selection on bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR), bisulfite sequencing, methylationspecific PCR and matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Two genes identified in this manner, RUNX3 and Testin (TES), were subsequently shown to harbor frequent tumor-specific epigenetic alterations in primary glioblastomas. This overall approach therefore provides a powerful means to identify candidate tumor-suppressor genes for subsequent evaluation and may lead to the identification of genes whose epigenetic dysregulation is integral to glioblastoma tumorigenesis.
Introduction
Comprehensive allelotyping of glioblastoma, the most common and most malignant of brain tumors, has shown that allelic loss is widespread, affecting nearly all chromosomes at frequencies ranging from 2 to 75% (von Deimling et al., 2000) . Particularly common regions of loss include areas on 6q, 9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q, 22q and Y (Kim et al., 1995; Mohapatra et al., 1998; Nishizaki et al., 1998; von Deimling et al., 2000; Collins, 2004) . To date, however, few tumor-suppressor genes have been definitively implicated in glioblastomas at these loci; somatic mutations of the remaining alleles have been demonstrated for TP53 on 17p (Chung et al., 1991; von Deimling et al., 1994; Ichimura et al., 2000) , PTEN on 10q Steck et al., 1997; Wang et al., 1997) and, to a lesser extent, RB1 on 13q (Henson et al., 1994; Ichimura et al., 1996) and homozygous deletions have been documented affecting the CDKN2A/p16/p14 locus on 9p (Ichimura et al., 1996 (Ichimura et al., , 2000 Ueki et al., 1996) . The identity of the putative tumor-suppressor genes at all other loci remains elusive.
Methylation of promoter regions, with corresponding downregulation of gene expression, has been implicated as an alternative mechanism to gene mutation for tumor-suppressor gene inactivation (Costello et al., 2000a; Esteller, 2003 Esteller, , 2005 Jain, 2003; Ballestar and Esteller, 2005) . In glioblastomas, for instance, frequent promoter hypermethylation has been noted for p14 arf and RB1 (Costello et al., 1996; Watanabe et al., 2002; Gonzalez-Gomez et al., 2003a, b) . Most approaches to evaluating methylation as a means of tumor-suppressor gene inactivation in glioblastomas have focused on individual candidate genes (Li et al., 1998 (Li et al., , 1999 Fan et al., 2002; Watanabe et al., 2002; Dallol et al., 2003; Gonzalez-Gomez et al., 2003a, b; Dickinson et al., 2004; Stone et al., 2004) . Although such studies have implicated methylation as a tumorigenic event in human gliomas, these approaches do not provide a means to identify novel genes not considered a priori to be candidates. In this regard, it is important to note that gliomas are extensively methylated across the tumor genome (Costello et al., 2000a) and that promoter hypermethylation is not necessarily tied to regions of allelic loss; integrated genetic and epigenetic approaches in gliomas have shown that many methylated genes are independent of regions affected by deletion (Zardo et al., 2002; Hong et al., 2003) . Thus, selected analysis of candidates, chosen because they lie in regions of allelic loss, could miss other putative tumor-related genes.
To address these problems, a number of screening methods have been developed to identify differentially methylated genes that may be involved in tumorigenesis (Herman et al., 1996; Kohno et al., 1998; Liang et al., 1998; Curtis and Goggins, 2005) , including restriction landmark genome scanning (RLGS) (Smiraglia et al., 1999; Costello et al., 2000a, b; Costello et al., 2002a, b; Zardo et al., 2002; Hong et al., 2003) , pharmaceutical unmasking of epigenetic alterations with 5-aza-dC coupled with cRNA microarray in tumor cell cultures (Yamashita et al., 2002; Lodygin et al., 2005; Morris et al., 2005) , and array-based combination of BAC clones and methylation-sensitive restrictive enzymes NotI or BssHII (Ching et al., 2005) . To identify genes potentially inactivated by methylation in human glioblastomas, we employed pharmaceutical unmasking of short-term cultured cells derived from three independent primary glioblastomas with 5-aza-dC, followed by cRNA microarray analysis. Validation of candidate genes was then carried out using a variety of approaches, including reverse transcription-polymerase chain reaction (RT-PCR), bisulfite sequencing, methylation-specific PCR (MSP) and base-specific cleavage analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS).
Results

Validation of demethylation treatment
To verify the effects of 5-aza-dC treatment in our system, we evaluated expression of the MGMT gene, which is known to be silenced by methylation in U87 glioma cells. RT-PCR verified that exposure of the U87 cells to 5-aza-dC induced re-expression of MGMT (data not shown), confirming that demethylation using 5-azadC was able to upregulate expression from a promoter known to be silenced by methylation in these cells.
Microarray analysis of cultured gliomas and candidate gene identification: TES, RUNX3, SERPINB5 and SFN We next performed oligonucleotide microarray analysis of duplicates of three short-term cultured glioblastomas (GLI56, GLI60 and GLI72), with each culture studied before and after 5-aza-dC treatment. To limit the inclusion of background hybridization expression, 3798 probe sets of 22 283 probe sets with raw expression values of less than 20 in all treated samples were excluded (see Supplementary data 1). The remaining 18 485 probe sets were then selected for a greater than or equal to threefold increase in average raw expression across all samples after demethylation by 5-aza-dC and a statistical significance (Po0.05) in all three glioma cultures. Fifty-three probe sets met these criteria. Owing to probe set redundancy, these 53 probe sets corresponded to 43 genes (see Supplementary data 2).
To further prioritize candidates, we searched for CpG islands in these 43 genes, since these mark regions of potential gene regulation by methylation; we found CpG islands in 22 of the 43 genes (Table 1) . CpG islands were located in potential promoter regions in 19 genes; whereas TLR2 and STAG3 harbored CpG islands in untranslated parts of exon 1 and KIAA0561 had 5 intragenic CpG islands (Table 1) . A literature review next demonstrated that four genes were particularly promising in light of evidence for tumor-suppressor gene properties and/or tumor-related epigenetic regulation in a variety of non-glial neoplasms: Testin (TES) (Tatarelli et al., 2000; Tobias et al., 2001) , RUNX3 (Kato et al., 2003; Kang et al., 2004; Kim et al., 2004; Tozawa et al., 2004; Imamura et al., 2005; Mori et al., 2005) , SERPINB5 (Domann et al., 2000; Sato et al., 2004) and SFN (Jeanteur, 2000; Suzuki et al., 2000; Umbricht et al., 2001; Gasco et al., 2002; Osada et al., 2002) . The possible association of promoter methylation and gene silencing in glioblastomas was a novel observation for these genes.
RT-PCR for validation in glioma cultures and evaluation of expression in normal brain Expression array data for these four genes was verified with RT-PCR on cDNA from the three cultured gliomas studied pre-and post-5-aza-dC treatment (Figure 1 ). GLI73 and U87 were also investigated, as was RNA derived from fetal and adult human brain and from cultured human astrocytes. RUNX3, TES, SER-PINB5 and SFN were all confirmed to be upregulated after treatment in GLI56, GLI60 and GLI72. Whereas TES expression was also induced in GLI73, RUNX3 was strongly expressed both before and after 5-aza-dC exposure, suggesting an unmethylated RUNX3 promoter in that cultured glioma (Figure 1 ).
None of these four genes were expressed in U87 prior to 5-aza-dC treatment, but all were upregulated after treatment (Figure 1 ). Normal fetal and adult human brain showed expression of TES and RUNX3, suggesting that downregulation of these genes in the cultured gliomas and U87 was tumor related. Re-expression of these genes following 5-aza-dC treatment thus strongly suggested that downregulation was related to promoter hypermethylation in gliomas. SFN and SERPINB5, however, had negligible expression in normal fetal and adult human brain, which indicates that these genes are silenced in normal nervous system cells rather than in a tumor-specific manner. In addition, SFN and SER-PINB5 expression in untreated cultured glioma samples were similar to the normal controls, further supporting the notion that silencing of these genes is cell-type specific rather than being tumor related.
Bisulfite sequencing of RUNX3 and TES promoters in cultured gliomas To evaluate the methylation status of the RUNX3 and TES promoters, these regions were bisulfite sequenced ( Figure 2 ). For RUNX3, a 341-bp fragment was sequenced around the transcription start site, covering 54 CpG dinucleotides; for TES, the fragment sequenced around the transcription start site was 536 bp in size and covered 70 CpG dinucleotides. Both promoter regions were divided into two adjacent fragments. Analysis of bisulfite-modified DNA of normal human adult brain tissue and leukocytes confirmed that the RUNX3 promoter was completely unmethylated and the TES promoter had only single scattered methylated CpG dinucleotides. Dense promoter hypermethylation was observed in all three cultured gliomas and U87 for both RUNX3 and TES. Of note, the RUNX3 promoter was unmethylated in GLI73, which was predicted by the strong expression of RUNX3 before demethylation. These results show concordance between promoter methylation and expression status for each of these genes.
Base-specific cleavage (MassCLEAVE) and MALDI TOF MS We used a mass spectrometry-based method (Ehrich et al., 2005) , which enables quantitative measurement of DNA methylation, to assess methylation levels in three candidate genes (RUNX3, TES, SFN). We studied the four short-term cultured glioblastomas, the glioma cell line U87, DNA derived from normal adult and fetal brain and from normal human astrocytes and neurons. The results confirm tumor-related hypermethylation in RUNX3 and TES (Figure 3 ). The quantitative method allowed statistical verification of these observations. The mean methylation ratio for RUNX3 was 11% (mean 95%CI ¼ 9-12%; median ¼ 7%, 1st quartile ¼ 5%, 3rd quartile ¼ 15%) in brain samples and 32% (mean 95%CI ¼ 24-39%; median ¼ 18%, 1st quartile ¼ 7%, 3rd quartile ¼ 49%) in the glioblastomas. For TES, the mean methylation was 16% (mean 95%CI ¼ 13-19%; median ¼ 12%, 1st quartile ¼ 6%, 3rd quartile ¼ 23%) for brain samples and 76% (mean 95%CI ¼ 68-85%; median ¼ 81%, 1st quartile ¼ 68%, 3rd quartile ¼ 100%) in the glioblastomas. These differences were statistically significant (P-value for RUNX3 o0.001; P-value for TES o0.001). Analysis of the SFN promoter region revealed generally high levels of DNA methylation (mean ¼ 99%) with no significant difference Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction; TES, Testin. Of note, due to chip redundancy more than one probeset number represented TES, SerpinB5 and SFN. The first five genes were followed up in detail. CpG islands in gene promoter indicate that the second group of 14 genes could be promising for future methylation analysis. CpG islands outside of transcription start sites were found for the last three genes.
HA , promoter hypermethylation is present in U87, GLI56, GLI60 and GLI72, but not in GLI73 or in normal brain and leukocyte DNA. For fragment 2 of RUNX3, promoter hypermethylation is present in U87 and GLI60, but not in GLI73 or normal adult brain (AB). These results are mirrored on MSP assays (far right panels), confirming that MSP accurately reflects promoter methylation status. (Bottom panel) For fragment 1 of TES, promoter hypermethylation is present in GLI56, GLI60, GLI73 and U87, but not in normal brain or leukocyte DNA. For fragment 2 of TES, promoter hypermethylation is present in GLI56, GLI60 and GLI73, but not in normal adult brain (AB) or leukocyte DNA. These results are mirrored on MSP assays (far right panels), again showing that MSP accurately reflects promoter methylation status. Of note, the methylation status of both RUNX3 and TES in these studies correlates with expression array and RT-PCR data (see Figure 1 ). M ¼ methylated allele-specific MSP assay; U ¼ unmethylated allele-specific MSP assay. A graphical representation of the CpG islands around the transcription start site for RUNX3 and TES accompanies the upper and lower panel. Size and location of bisulfite sequenced fragments and the fragments analysed by MALDI-TOF are indicated. CpG dinucleotides incorporated into the MSP primer sequences are highlighted above the bisulfite sequencing results. Figures 1 and 3 ). Of note, bisulfite sequencing and MSP identified the RUNX3 promoter of GLI72 as being hypermethylated, but this was not found on MALDI-TOF; however, the MALDI-TOF analysis was performed more upstream of the transcription start site and hypermethylation increased from fragment 1 to fragment 2 of the bisulfite sequencing. These findings suggest preferential hypermethylation at sites closer to the transcriptional start site in RUNX3.
MSP of candidate genes in primary glioma samples The incidence of TES and RUNX3 promoter hypermethylation was evaluated in an independent series of 34 primary glioblastoma specimens (Table 2) . Primer design for these assays was based on bisulfite sequencing results and incorporated two CpG dinucleotides that were regularly methylated in the cultured gliomas and unmethylated in the normal adult human brain. Primer sequences are available on request. Promoter hypermethylation of TES and RUNX3 was observed in 58% (18/31) and 56.2% (18/32) of glioblastomas, respectively (Figure 4 ). Of note, as an internal control for tumor selection, we also evaluated MGMT promoter methylation status in these primary gliomas. MGMT promoter methylation was found in 52% (16/31) of the glioblastomas (Table 2) , in keeping with the reported ranges of MGMT promoter methylation in 45% (Kamiryo et al., 2004; Hegi et al., 2005) to 68% (Blan et al., 2004; Hegi et al., 2004) of glioblastomas.
Discussion
Microarray analysis coupled with pharmacologic demethylation of cultured tumor cells is a useful means for investigating genome-wide epigenetic events and has been successfully used for this purpose in other cancer types (Yamashita et al., 2002; Lodygin et al., 2005; Morris et al., 2005) . Applying this approach to malignant gliomas identified 22 novel candidate genes, of which four were pursued for validation studies using multiple independent techniques (RT-PCR, bisulfite sequencing, MALDI-TOF and MSP). Two of these genes revealed frequent epigenetic alterations in primary The RUNX3 target region was located upstream of the transcription start site. Methylation levels are elevated in U87 and GLI56; GLI60 also shows slightly elevated methylation; but GLI72 and GLI73 have methylation levels comparable to the control samples. Except for GLI72 this confirms bisulfite sequencing and MSP results (see text).
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gliomas and two were silenced in a cell-type specific manner.
Such approaches are powerful screening tools, albeit with some caveats. One caveat is that gene expression is under complex regulation. Demethylation and subsequent upregulation of various molecules could lead to increased expression of genes that may be embedded in a regulatory network and therefore indirectly affected by methylation changes in other genes. Such genes are likely to be identified in this type of initial microarray screen. In this regard, simultaneous upregulation of downstream targets of epigenetically silenced genes could also further complicate candidate gene prioritization. For RUNX3 and TES, we confirmed tumor-specific methylation by analysing primary glioblastomas. However, the complex networking of gene regulation could explain lack of correlations between methylation and expression differences in other genes.
Particular problems in interpreting the significance of such studies in malignant gliomas are lack of knowledge of cells of origin and inherent heterogeneity in these tumors (Louis, 2006) . Knowledge of glioma cell of origin is important since certain genes may be methylated and silenced in the normal tissues from which tumors arise; in this situation, methylation-related promoter inactivation is far less likely to be related to tumorigenesis. To address this issue, we undertook comparative RT-PCR analysis of lysates of whole brain as well as tumor tissue. Lack of expression in the normal brain, which includes the gamut of central nervous system cell types, would suggest cell-type specific rather than tumor-related gene silencing. For example, although SERPINB5 and SFN expression was highly induced after demethylation, they were not expressed in normal fetal and adult human brain; SERPINB5 Figure 4 n ID Tissue RUNX3 TES MGMT 
expression is known to be expressed in a cell-type specific manner and regulated by promoter hypermethylation in other tissues (Futscher et al., 2002) . Cell-type specific methylation of SFN was confirmed following an MSP assay described elsewhere (data not shown) (Bhatia et al., 2003) . The approach taken in this paper requires an abundance of cultured cells for demethylation treatment. Given that extensive passaging can have epigenetic effects (Matsumura et al., 1989) , we opted to use nonimmortalized, short-term cultured glioblastomas. However, not all cultured primary glioblastomas yield high cell counts within relatively few passages, which are required to allow early intersample synchronization. As a result, although it is tempting to use readily available, immortalized glioma cell lines such as U87, extensive passaging of such lines renders controls for intersample differences impossible and may have profound epigenetic effects. For example, MALDI-TOF analysis of randomly selected genes in U87 indicated heavy global hypermethylation rather than the differential promoter hypermethylation that we found in our short-term cultured gliomas (data not shown). We would therefore advocate use of primary cultured gliomas rather than glioma cell lines for candidate gene identification in future studies of this type.
Overall, these data remain descriptive and are aimed primarily at candidate gene identification and prioritization. Future functional studies are needed to further evaluate these candidates specifically in gliomas but, as discussed below, evidence already supports a possible role for each of these genes in tumorigenesis. For example, RUNX3 promoter hypermethylation occurs in many different human cancer types (Kato et al., 2003; Kang et al., 2004; Kim et al., 2004; Tozawa et al., 2004; Imamura et al., 2005; Mori et al., 2005) , sometimes in association with loss of one RUNX3 allele (Kato et al., 2003; Xiao and Liu, 2004) . In some tumors, RUNX3 methylation correlates with tumor grade, clinical outcome and/or tumor cell behavior (Kang et al., 2004; Kim et al., 2004; Tozawa et al., 2004; Schulmann et al., 2005; Wei et al., 2005) . In gastric cancer, loss of RUNX3 expression results in reduced sensitivity to growthinhibiting and apoptosis-inducing activities, causing epithelial hyperplasia and eventually cancer (Li et al., 2002) . These supporting data, as well as the studies implicating RUNX3 in other human cancers, indicate an unmethylated RUNX3 promoter in the majority of cases. Our data suggest a role for RUNX3 inactivation in at least a subset of glioblastomas.
Loss of TES expression also occurs frequently in various cancers (Tatarelli et al., 2000; Tobias et al., 2001) . Missense mutations are scarce and homozygous deletions have not been observed, consistent with CpG promoter hypermethylation being a mechanism of TES gene inactivation (Tobias et al., 2001) . Forced TES expression in HeLa or OVCAR5 cells profoundly reduces cancer cell growth (Tobias et al., 2001) . Adenoviral transduction of the TES gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction (Sarti et al., 2005) . Frequent promoter hypermethylation in a subset of glioblastomas is therefore consistent with the possibility of similar tumorrelated inactivation in high-grade gliomas.
RUNX3 and TES map to 1p36 and 7q31.2, respectively. Allelic loss of 1p and 7q has been described in glioblastomas, albeit at low frequencies. Loss of 1p occurs in approximately between 6 and 20% of glioblastomas (Wooten et al., 1999; von Deimling et al., 2000; Schmidt et al., 2002) and, in combination with 19q loss, may indicate better prognosis and response to therapy (Ino et al., 2000; Schmidt et al., 2002; Hill et al., 2003) . Loss of 7q has been found in approximately 9-12% of glioblastomas (Wooten et al., 1999; von Deimling et al., 2000) . Notably however, promoter hypermethylation of RUNX3 and TES may not closely associate with allelic loss, since genome-wide analyses of glioblastomas have shown promoter hypermethylation occurring frequently in loci not affected by allelic loss (Costello et al., 2000a) . In addition, in other tumor types, promoter hypermethylation of both alleles has been identified as a primary mechanism for TES gene inactivation (Tobias et al., 2001) .
In summary, we have presented the results of a screening approach designed to detect genes potentially regulated by promoter methylation. The screen and the subsequent validation steps have taken into account a number of pitfalls in such an analysis, including some that are particularly germane to the study of malignant gliomas. The genes studied in detail may prove significant in further functional studies and in translational studies as markers, as could the remaining candidate genes. The reporting of this gene list should encourage further studies of these candidates. Finally, from a therapeutic point of view, the study of such genes could be of interest given that the reversible nature of promoter hypermethylation may be amendable to pharmaceutical targeting in the future.
Materials and methods
Glioma samples
Tissue samples were collected with patient consent from Massachusetts General Hospital (MGH; Boston, MA, USA) under the approval of the MGH Institutional Review Board and from University Hospital Charite´(Berlin, Germany) after ethics committee approval and patient consent. Four primary glioblastomas were placed in short-term culture for 5-aza-dC treatment (see below), and the primary tumors and short-term cultures were used for analyses. Thirty-four primary glioblastomas were randomly selected from patients treated at MGH and University Hospital Charite´; the majority of specimens were formalin-fixed and paraffin-embedded. All tumors were classified and graded according to the 2000 WHO criteria (Kleihues and Cavenee, 2000) .
Cell culture
In addition to the immortalized U87 glioblastoma cell line, nonimmortalized short-term cultured glioma cell lines (GLI56, GLI60, GLI72, GLI73) were established from four human primary glioblastomas and maintained in Dulbecco's modified Eagle's medium without L-glutamine (Gibco, Invitrogen Downregulation of RUNX3 and TES W Mueller et al Corporation, Carlsbad, CA, USA). The medium was supplemented with 1% L-glutamine (Gibco, Invitrogen Corporation, Carlsbad, CA, USA), heat-inactivated 10% fetal bovine serum (Sigma Aldrich Corporation, St Louis, MO, USA), 1% penicillin-streptomycin (Gibco, Invitrogen Corporation, Carlsbad, CA, USA) and grown at 371C in a humidified atmosphere of 5% CO 2 /95% air. Before drug treatment, the neoplastic status of the short-term cultured cell lines was established by verifying that genetic and chromosomal alterations found in the primary tumors (homozygous deletion of CDKN2A/p16 and loss of heterozygosity of 10q) were retained in the cultured cells (data not shown).
5-aza-dC treatment of cells
Treatment with 5 mM 5-aza-dC (Sigma Aldrich Corporation, St Louis, MO, USA) was carried out for 96 h. To minimize interand intratumoral differences in drug response, the four nonimmortalized short-term cultured gliomas were consistently treated 16 h after being seeded, using cells of the lowest common passage (P15). The established glioma cell line U87 was cultured and treated simultaneously as an internal experimental control. All experiments were carried out in triplicate.
DNA and RNA isolation Total RNA was isolated from four short-term cultured primary glioma cell lines, glioma cell line U87 and 10 unrelated snap frozen primary glioblastoma tissues using TRIzol (Invitrogen Life Technologies Inc., Carlsbad, CA, USA), followed by postextraction clean-up utilizing the RNaeasy Mini kit (Qiagen, Valencia, CA, USA). Genomic DNA from short-term cultured gliomas and formalin-fixed, paraffinembedded tissues was extracted using the DNA Isolation Kit according to the manufacturer's instructions (Gentra Systems, Minneapolis, MN, USA). Genomic DNA from leukocytes and commercially available RNA and DNA from adult and fetal human brain (US Biological, Swampscott, MA, USA) were available as experimental controls.
Microarray and RT-PCR analysis
We performed oligonucleotide microarray analysis of duplicates of three out of four primary short-term cultured glioblastomas (Gene expression omnibus (GEO) #: GSE4717). The fourth cultured glioma was not used for microarray analysis since growth was not robust at the lowest common passage to provide enough cells; this line was used only for subsequent validation. Biotin-labeled RNA (15 mg) was fragmented and hybridized to GeneChip Human Genome U133A (Affymetrix, Santa Clara, CA, USA). With 22 283 probe sets; the U133A chip analyses the expression level of 18 400 transcripts and variants including 14 500 well-characterized genes. Linear scaling normalized raw expression values, so that the mean array intensity was identical for all scans. To exclude background hybridization expression, a lower expression threshold was set at 20 in the treated samples. Differentially expressed transcripts were initially identified by the standard two-sample t-test using Vector Xpression (InforMax Inc., 7305 Executive Way, Frederick, MD, USA). Owing to the small number of cell lines being studied, we began with a less stringent analysis in order to allow for a greater number of potential candidate genes for follow-up; the goal was to undertake a broad screen of differentially expressed transcripts, and then to perform rigorous followup validation steps.
For RT-PCR, first-strand cDNA was synthesized from 1 mg DNAse-treated total RNA using the SuperScriptTM FirstStrand Synthesis System (Invitrogen, Carlsbad, CA, USA) and oligo-dT primers. Exon-overlapping cDNA-specific primers were designed for all analysed genes. PCR was facilitated by AmpliTaq Gold PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Standard PCR amplification protocols were used with an initial denaturation and enzyme activation step of 951C for 15 min followed by 951C denaturation, individual annealing temperatures and 721C extension of 30 s each for 32 cycles and a final extension at 721C for 10 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) amplification was used as an internal control for cDNA quality and quantity. Amplified products were electrophoretically separated on 1.2% agarose gels, and visualized with ethidium bromide.
CpG island identification
CpG islands at the 5 0 promoter region that included the ATG start sites or proposed transcriptional start sites were identified using online tools. Initially, the cDNA sequence of the target gene was blasted against the human genome using the 'BLAT' function of the Human (Homo sapiens) Genome Browser Gateway (http://genome.ucsc.edu/cgi-bin/hgGateway?org ¼ human), generating CpG islands and their sequences. Once CpG islands were identified, the genomic sequence was blasted again using the 'Nucleotide-nucleotide BLAST (blastn)' of the NCBI homepage (www.ncbi.nlm.nih.gov/blast) and BAC clones containing the target gene and its promoter region including the CpG island were selected for primer design. Finally, CpG islands characterized in the initial Human Genome Browser Gateway blast were verified with the CpG island searcher (http://cpgislands.usc.edu/) and primer design was facilitated using MethPrimer (www.urogene.org/methprimer/).
Bisulfite modification
Sodium bisulfite modification was performed using the CpGenome Universal DNA Modification Kit (Chemicon International, Serologicals Corporation, Temecula, CA, USA). Universally methylated DNA (CpGenome Universal Methylated DNA, Chemicon International, Serologicals Corporation, Temecula, CA, USA) and unmethylated DNA from normal blood samples were treated with bisulfite by the same method. Modification of 1 mg genomic DNA was performed overnight (16 h). After desalting, desulfonation and additional desalting, modified DNA was eluted in TE buffer at a concentration of 20 ng/ml, aliquotted and stored at À801C for future use.
Bisulfite sequencing
Initially, bisulfite-modified DNA of a target promoter region was amplified, electrophoretically separated and visualized by ethidium bromide. Second, the PCR product was plasmidincorporated using One Shot Escherichia coli cells and the TOPO TA Cloning Kit (Invitrogen Life Technologies Inc., Carlsbad, CA, USA). Cells were then plated and grown overnight on prewarmed LB plates containing X-gal and 50 mg/ml ampicillin and 50 mg/ml kanamycin. Colony PCR was performed on ten white colonies to validate the insert. Before sequencing, the PCR products were purified (QIAquick PCR Purification Kit, Qiagen, Valencia, CA, USA). Sequencing was performed on an ABI 3730XL DNA Sequencer (ABI, Foster City, CA, USA) and analysed using Sequencher Software version 4.2. (Gene Codes Corporation, Ann Arbor, MI, USA).
Methylation-specific PCR
The promoter regions of RUNX3, TES and MGMT were analysed by bisulfite sequencing and MSP. Primers used in the MSP assays were chosen either based on the bisulfite sequencing analysis results (i.e., TES) or taken from previous publications investigating promoter hypermethylation by MSP (i.e., RUNX3 (Li et al., 2004) and MGMT (Esteller et al., 1999) ). Primers were designed to contain at least two CpGs each and multiple MSP assays were established to 'map' different parts of the CpG island. Primer sequences and conditions are available upon request. All experiments were accompanied by suitable positive controls for methylated (M) and unmethylated (U) primers. Amplified products were electrophoresed on 1.2% agarose gels, and visualized with ethidium bromide.
Base-specific cleavage (MassCLEAVE) and MALDI TOF MS We used a MALDI-TOF MS-based method enabling quantitative characterization of methylation changes in high throughput to allow us to validate candidate genes identified by our gene expression analysis. In brief, the method uses an assay concept originally developed for comparative sequence analysis by MALDI-TOF MS (Stanssens et al., 2004) . The assay, termed MassCLEAVE, features PCR amplification of target regions between 200 and 1000 bases in length, whereby one of the PCR primers is tagged with a T7 RNA polymerase promoter. The PCR product is then transcribed into a single stranded RNA transcript, which is subsequently cleaved in a base-specific manner. The cleavage products are analysed by MALDI-TOF MS. Determination of the molecular mass of the cleavage products allows crosscorrelation of the experimental mass spectrum with an in silico mass spectrum generated from a reference sequence. Changes in mass signals can be identified automatically and can be interpreted through compositional analysis. This then allows identification of sequence changes in the target region. Details of the use of base-specific cleavage and MALDI-TOF MS for highthroughput, quantitative analysis of genomic methylation have been published elsewhere (Ehrich et al., 2005) .
